Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Genetic Basis of COVID-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04384250
Recruitment Status : Recruiting
First Posted : May 12, 2020
Last Update Posted : April 7, 2022
Information provided by (Responsible Party):
Ali Sobh, Mansoura University

Brief Summary:
We will study genetic factors causing severe disease due to infection with SARS-COV-2 which may help to find targeted therapy

Condition or disease Intervention/treatment
Genetic Basis of COVID-19 Infection Diagnostic Test: Whole Exome Sequencing

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Genetic Factors Influencing the Response to Infection With SARS-COV-2
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

Intervention Details:
  • Diagnostic Test: Whole Exome Sequencing
    Genetic study of patients

Primary Outcome Measures :
  1. Mutations leading to increase susceptibility to SARS-COV-2 infection [ Time Frame: 12 months ]
    Genetic susceptibility to COVID-19

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
COVID-19 positive patients

Inclusion Criteria:

  • severe COVID-19 infection

Exclusion Criteria:

  • Comorbidity ((DM, hypertension, Chronic liver or Kidney diseases, HIV, morbid obesity, Malignancy, Immunosuppressive therapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04384250

Layout table for location contacts
Contact: Ali Sobh, MD +201000911288
Contact: Marwa Elnagdy, MD +201010645060

Layout table for location information
Mansoura University Recruiting
Mansoura, Dakahlyia, Egypt, 35516
Contact: Ali Sobh, MD         
Sponsors and Collaborators
Mansoura University
Layout table for additonal information
Responsible Party: Ali Sobh, Lecturer of Pediatric Immunology, Mansoura University Identifier: NCT04384250    
Other Study ID Numbers: RP:20.05.70
First Posted: May 12, 2020    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ali Sobh, Mansoura University:
SARS-COV-2, Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Disease Attributes
Pathologic Processes
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases